Association between SLCO1B3 gene polymorphism and prostate cancer risk: A meta-analytic study


  • Qunshan Shen Department of Urology, The 105th Hospital of People's Liberation Army, Hefei 230061
  • Yu Liang Department of Urology, The 105th Hospital of People's Liberation Army, Hefei 230061
  • Haibo Li Department of Urology, The 105th Hospital of People's Liberation Army, Hefei 230061
  • Mei Chen Department of Urology, The 105th Hospital of People's Liberation Army, Hefei 230061
  • Jun Zhang Department of Urology, The 105th Hospital of People's Liberation Army, Hefei 230061
  • Pengcheng Feng Department of Urology, The 105th Hospital of People's Liberation Army, Hefei 230061
  • Jie Meng Department of Urology, The 105th Hospital of People's Liberation Army, Hefei 230061
  • Haiyun Yu Department of Urology, The 105th Hospital of People's Liberation Army, Hefei 230061



Meta-analysis, Prostate cancer, rs4149117, SLCO1B3 gene polymorphism


The aim of this meta-analysis was to assess the association between SLCO1B3 gene polymorphism and prostate cancer risk. PubMed, Embase, Cochrane Library, and Web of Science from inception to September 2017 were searched. Three authors independently selected studies, extracted data and assessed risk of bias. 5 articles published from 2008 to 2013 with 840 patients were included in this meta-analysis and were from Japan, USA and China. The prostate cancer risk of SLCO1B3 (rs4149117, GG) was markedly higher than that of SLCO1B3 (rs4149117, TT/TG, RR= 0.44, 95%CI: 0.39-0.49, p<0.00001), rs4149117 (TT, RR= 0.37, 95%CI: 0.32-0.42, p<0.00001) and rs4149117 (TG, RR= 0.07, 95%CI: 0.05-0.10, p<0.00001). 2 or 5 years risk  free symptoms (RFS) of prostate cancer patient with SLCO1B3 (rs4149117, GG) was markedly higher than that of SLCO1B3 (rs4149117, TT/TG) (RR= -0.17, 95% CI: -0.27--0.07, p= 0.001 and RR= -0.08, 95% CI: -0.16-0.00, p= 0.004). However, no evidence showed there existed significant statistical relationship between SLCO1B3 (rs4149117) and 10 years RFS of prostate cancer (RR= -0.07, 95% CI: -0.19-0.06, p= 0.29). These data suggest that SLCO1B3 (rs4149117, GG) enhanced the RFS of prostate cancer.


Download data is not yet available.


Ayalasomayajula S, Han Y, Langenickel T, Malcolm K, Zhou W, Hanna I, Alexander N, Natrillo A, Goswami B, Hinder M, Sunkara G. In vitro and clinical evaluation of OATP-mediated drug interaction potential of sacubitril/valsartan (LCZ696). J Clin Pharm Ther. 2016; 41: 424-31.

Bedewy AM, El-Maghraby SM. Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy? Hematology 2013; 18: 211-16.

Ben-Josef AM, Chen J, Wileyto P, Doucette A, Bekelman J, Christodouleas J, Deville C, Vapiwala N. Effect of eischens yoga during radiation therapy on prostate cancer patient symptoms and quality of life: A randomized phase II trial. Int J Radiat Oncol Biol Phys. 2017; 98: 1036-44.

de Morree ES, Bottcher R, van Soest RJ, Aghai A, de Ridder CM, Gibson AA, Mathijssen RH, Burger H, Wiemer EA, Sparreboom A, de Wit R, van Weerden WM. Loss of SLCO1B3 drives taxane resistance in prostate cancer. Br J Cancer. 2016; 115: 674-81.

Evangeli L, Ioannis S, Valentinos K, Antigony M, Elli I, Eleftheria H, Vasiliki G, Evangelos B. SLCO1B3 screening in colorectal cancer patients using High-Resolution Melting Analysis method and immunohistochemistry. Tumour Biol. 2017; 39: 1010428317691176.

George S, Miao D, Demetri GD, Adeegbe D, Rodig SJ, Shukla S, Lipschitz M, Amin-Mansour A, Raut CP, Carter SL, Hammerman P, Freeman GJ, Wu CJ, Ott PA, Wong KK, Van Allen EM. Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma. Immunity 2017; 46: 197-204.

Hieronymus H, Schultz N, Gopalan A, Carver BS, Chang MT, Xiao Y, Heguy A, Huberman K, Bernstein M, Assel M, Murali R, Vickers A, Scardino PT, Sander C, Reuter V, Taylor BS, Sawyers CL. Copy number alteration burden predicts prostate cancer relapse. Proc Natl Acad Sci USA. 2014; 111: 11139-44.

Koyama K, Kagamu H, Miura S, Hiura T, Miyabayashi T, Itoh R, Kuriyama H, Tanaka H, Tanaka J, Yoshizawa H, Nakata K, Gejyo F. Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage. Clin Cancer Res. 2008; 14: 6770-79.

Medioni J, Deplanque G, Ferrero JM, Maurina T, Rodier JM, Raymond E, Allyon J, Maruani G, Houillier P, Mackenzie S, Renaux S, Dufour-Lamartinie JF, Elaidi R, Lerest C, Oudard S. Phase I safety and pharmacodynamic of inecalcitol, a novel VDR agonist with docetaxel in metastatic castration-resistant prostate cancer patients. Clin Cancer Res. 2014; 20: 4471-77.

Montgomery B, Eisenberger MA, Rettig MB, Chu F, Pili R, Stephenson JJ, Vogelzang NJ, Koletsky AJ, Nordquist LT, Edenfield WJ, Mamlouk K, Ferrante KJ, Taplin ME. Androgen Receptor Modulation Optimized for Response (ARMOR) phase I and II studies: Galeterone for the treatment of castration-resistant prostate cancer. Clin Cancer Res. 2016; 22: 1356-63.

Obara W, Sato F, Takeda K, Kato R, Kato Y, Kanehira M, Takata R, Mimata H, Sugai T, Nakamura Y, Fujioka T. Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer. Cancer Sci. 2017; 108: 1452-57.

Pei Q, Yang L, Tan HY, Liu SK, Liu Y, Huang L, Li RH, Wan Q, Huang J, Guo CX, Zuo XC, Li J, Yang GP. Effects of genetic variants in UGT1A1, SLCO1B3, ABCB1, ABCC2, ABCG2, ORM1 on PK/PD of telmisartan in Chinese patients with mild to moderate essential hypertension. Int J Clin Pharmacol Ther. 2017; 55: 659-65.

Petrioli R, Roviello G, Fiaschi AI, Laera L, Miano ST, De Rubertis G, Barbanti G, Bianco V, Brozzetti S, Francini E. Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: A single-institution experience. Med Oncol. 2015; 32: 52.

Pu Z, Wang Q, Xie H, Wang G, Hao H. Clinical, pathological and prognostic significance of survivin expression in renal cell carcinoma: A meta-analysis. Oncotarget 2017; 8: 19825-33.

Pu Z, Zhang X, Chen Q, Yuan X, Xie H. Establishment of an expression platform of OATP1B1 388GG and 521CC genetic polymorphism and the therapeutic effect of tamoxifen in MCF-7 cells. Oncol Rep. 2015; 33: 2420-28.

Shimizu K, Takashima T, Yamane T, Sasaki M, Kageyama H, Hashizume Y, Maeda K, Sugiyama Y, Watanabe Y, Senda M. Whole-body distribution and radiation dosimetry of [11C]telmisartan as a biomarker for hepatic organic anion transporting polypeptide (OATP) 1B3. Nucl Med Biol. 2012; 39: 847-53.

Suga T, Yamaguchi H, Sato T, Maekawa M, Goto J, Mano N. Preference of conjugated bile acids over unconjugated bile acids as substrates for OATP1B1 and OATP1B3. PLoS ONE. 2017; 12: e0169719.

Vasarainen H, Lahdensuo K, Savolainen R, Ruutu M, Taari K, Rannikko A. Diffusion-weighted magnetic resonance imaging in prostate cancer patients on active surveillance one year after diagnosis and before repeat biopsy. Scand J Urol. 2013; 47: 456-61.

Wang Z, Qu L, Yao J, Yang X, Li G, Zhang Y, Li J, Wang X, Bai J, Xu G, Deng X, Yang N, Wu C. An EAV-HP insertion in 5' Flanking region of SLCO1B3 causes blue eggshell in the chicken. PLoS Genet. 2013; 9: e1003183.

Zheng H, Liu X, Zhang J, Rice SJ, Wagman M, Kong Y, Zhu L, Zhu J, Joshi M, Belani CP. Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer. Oncotarget 2016; 7: 56233-40.

Zhou T, Zeng SX, Ye DW, Wei Q, Zhang X, Huang YR, Ye ZQ, Yang Y, Zhang W, Tian Y, Zhou FJ, Jie J, Chen SP, Sun Y, Xie LP, Yao X, Na YQ, Sun YH. A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer. PLoS ONE. 2015; 10: e0117002.




How to Cite

Shen, Q., Y. Liang, H. Li, M. Chen, J. Zhang, P. Feng, J. Meng, and H. Yu. “Association Between SLCO1B3 gene polymorphism and Prostate Cancer Risk: A meta-Analytic Study”. Bangladesh Journal of Pharmacology, vol. 13, no. 1, Mar. 2018, pp. 98-105, Mar 25, 2018, doi:10.3329/bjp.v13i1.34544.